ACEI and AII receptor blockers (ARB) are considered as agents not only providing adequate control of arterial pressure but having additional nephroprotective effects. Tolerance to ACEI is lower than that of ARB: such side effects as coughing and angioneurotic edema occur much less on sartan therapy than ACEI one. Randomized clinical studies on investigation of nephroprotective properties of ARB were conducted with Lozartan, Irbesartan, Valsartan and Telmisartan drugs predominantly in patients with Diabetes mellitus and chronic kidney disease of various degrees. The evidence basis on nephroprotective effect of this type of drugs is discussed in the literature review.